Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):1053–1057. doi: 10.1128/aac.41.5.1053

Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.

C Thauvin-Eliopoulos 1, M F Tripodi 1, R C Moellering Jr 1, G M Eliopoulos 1
PMCID: PMC163849  PMID: 9145868

Abstract

The in vivo activities of piperacillin-tazobactam and cefepime were compared with those of ticarcillin-clavulanate, ceftazidime, cefotaxime, and imipenem in a rat model of intra-abdominal abscess with a strain of Klebsiella pneumoniae elaborating an extended-spectrum beta-lactamase (TEM-26). With the exception of ceftazidime, all of the antimicrobial agents significantly reduced bacterial counts within abscesses at the end of therapy compared with those in untreated controls. Residual viable cell counts (mean +/- standard deviation in log10 CFU/gram) were as follows: control, 8.76 +/- 0.97; ceftazidime, 8.00 +/- 0.76; piperacillin-tazobactam, 3.87 +/- 1.72; ticarcillin-clavulanate, 3.74 +/- 1.34; cefepime, 3.15 +/- 1.19; cefotaxime, 2.61 +/- 0.77; imipenem, 2.41 +/- 0.93. Imipenem was more effective than either of the inhibitor combinations (P < 0.05). Cefotaxime was unexpectedly effective given its poor in vivo activity against this organism in our earlier studies, which used a different dose and total duration of therapy (L. B. Rice, J. D. C. Yao, K. Klimm, G. M. Eliopoulos, and R. C. Moellering, Jr., Antimicrob. Agents Chemother. 35:1243-1244, 1991). These observations suggest that the effectiveness of cephalosporins in the treatment of experimental infections caused by extended-spectrum beta-lactamase-producing K. pneumoniae may be highly dependent on dosing regimens, even for a specific organism and site of infection.

Full Text

The Full Text of this article is available as a PDF (233.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbhaiya R. H., Forgue S. T., Gleason C. R., Knupp C. A., Pittman K. A., Weidler D. J., Martin R. R. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother. 1990 Jun;34(6):1118–1122. doi: 10.1128/aac.34.6.1118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbhaiya R. H., Forgue S. T., Gleason C. R., Knupp C. A., Pittman K. A., Weidler D. J., Movahhed H., Tenney J., Martin R. R. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992 Mar;36(3):552–557. doi: 10.1128/aac.36.3.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bächer K., Schaeffer M., Lode H., Nord C. E., Borner K., Koeppe P. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother. 1992 Sep;30(3):365–375. doi: 10.1093/jac/30.3.365. [DOI] [PubMed] [Google Scholar]
  4. Caron F., Gutmann L., Bure A., Pangon B., Vallois J. M., Pechinot A., Carbon C. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase. Antimicrob Agents Chemother. 1990 Nov;34(11):2070–2074. doi: 10.1128/aac.34.11.2070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fantin B., Pangon B., Potel G., Caron F., Vallée E., Vallois J. M., Mohler J., Buré A., Philippon A., Carbon C. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase. Antimicrob Agents Chemother. 1990 Apr;34(4):581–586. doi: 10.1128/aac.34.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fournier J. L., Ramisse F., Jacolot A. C., Szatanik M., Petitjean O. J., Alonso J. M., Scavizzi M. R. Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 1996 Feb;40(2):325–330. doi: 10.1128/aac.40.2.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jacobs M. R., Aronoff S. C., Johenning S., Shlaes D. M., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1986 Jun;29(6):980–985. doi: 10.1128/aac.29.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jacoby G. A., Medeiros A. A. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991 Sep;35(9):1697–1704. doi: 10.1128/aac.35.9.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jett B. D., Ritchie D. J., Reichley R., Bailey T. C., Sahm D. F. In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother. 1995 May;39(5):1187–1190. doi: 10.1128/aac.39.5.1187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jones R. N., Kehrberg E. N., Erwin M. E., Anderson S. C. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group. Diagn Microbiol Infect Dis. 1994 Aug;19(4):203–215. doi: 10.1016/0732-8893(94)90033-7. [DOI] [PubMed] [Google Scholar]
  11. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983 Nov-Dec;11(6):315–317. doi: 10.1007/BF01641355. [DOI] [PubMed] [Google Scholar]
  12. Leleu G., Kitzis M. D., Vallois J. M., Gutmann L., Decazes J. M. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1994 Feb;38(2):195–199. doi: 10.1128/aac.38.2.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Medeiros A. A. Nosocomial outbreaks of multiresistant bacteria: extended-spectrum beta-lactamases have arrived in North America. Ann Intern Med. 1993 Sep 1;119(5):428–430. doi: 10.7326/0003-4819-119-5-199309010-00015. [DOI] [PubMed] [Google Scholar]
  14. Mentec H., Vallois J. M., Bure A., Saleh-Mghir A., Jehl F., Carbon C. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob Agents Chemother. 1992 Sep;36(9):1883–1889. doi: 10.1128/aac.36.9.1883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Meyer K. S., Urban C., Eagan J. A., Berger B. J., Rahal J. J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993 Sep 1;119(5):353–358. doi: 10.7326/0003-4819-119-5-199309010-00001. [DOI] [PubMed] [Google Scholar]
  16. Papanicolaou G. A., Medeiros A. A. Discrimination of extended-spectrum beta-lactamases by a novel nitrocefin competition assay. Antimicrob Agents Chemother. 1990 Nov;34(11):2184–2192. doi: 10.1128/aac.34.11.2184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pefanis A., Thauvin-Eliopoulos C., Eliopoulos G. M., Moellering R. C. Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis. J Antimicrob Chemother. 1993 Aug;32(2):307–312. doi: 10.1093/jac/32.2.307. [DOI] [PubMed] [Google Scholar]
  18. Philippon A., Labia R., Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1989 Aug;33(8):1131–1136. doi: 10.1128/aac.33.8.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Quinn J. P., Miyashiro D., Sahm D., Flamm R., Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1989 Sep;33(9):1451–1456. doi: 10.1128/aac.33.9.1451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rice L. B., Carias L. L., Bonomo R. A., Shlaes D. M. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy. J Infect Dis. 1996 Jan;173(1):151–158. doi: 10.1093/infdis/173.1.151. [DOI] [PubMed] [Google Scholar]
  21. Rice L. B., Carias L. L., Shlaes D. M. In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1994 Nov;38(11):2663–2664. doi: 10.1128/aac.38.11.2663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rice L. B., Marshall S. H., Carias L. L., Sutton L., Jacoby G. A. Sequences of MGH-1, YOU-1, and YOU-2 extended-spectrum beta-lactamase genes. Antimicrob Agents Chemother. 1993 Dec;37(12):2760–2761. doi: 10.1128/aac.37.12.2760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rice L. B., Willey S. H., Papanicolaou G. A., Medeiros A. A., Eliopoulos G. M., Moellering R. C., Jr, Jacoby G. A. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990 Nov;34(11):2193–2199. doi: 10.1128/aac.34.11.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rice L. B., Yao J. D., Klimm K., Eliopoulos G. M., Moellering R. C., Jr Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother. 1991 Jun;35(6):1243–1244. doi: 10.1128/aac.35.6.1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sader H. S., Pfaller M. A., Jones R. N. Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 1994 Dec;20(4):203–208. doi: 10.1016/0732-8893(94)90004-3. [DOI] [PubMed] [Google Scholar]
  26. Sanders C. C. Cefepime: the next generation? Clin Infect Dis. 1993 Sep;17(3):369–379. [PubMed] [Google Scholar]
  27. Sirot D., Sirot J., Labia R., Morand A., Courvalin P., Darfeuille-Michaud A., Perroux R., Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. J Antimicrob Chemother. 1987 Sep;20(3):323–334. doi: 10.1093/jac/20.3.323. [DOI] [PubMed] [Google Scholar]
  28. Smith C. E., Tillman B. S., Howell A. W., Longfield R. N., Jorgensen J. H. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1990 Jun;34(6):1290–1293. doi: 10.1128/aac.34.6.1290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Thauvin C., Eliopoulos G. M., Willey S., Wennersten C., Moellering R. C., Jr Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb;31(2):139–143. doi: 10.1128/aac.31.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tjandramaga T. B., Mullie A., Verbesselt R., De Schepper P. J., Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1978 Dec;14(6):829–837. doi: 10.1128/aac.14.6.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wise R., Logan M., Cooper M., Andrews J. M. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 Jun;35(6):1081–1084. doi: 10.1128/aac.35.6.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES